News - Page 75 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article “After the Ecstasy, the Laundry” – Shayla Love’s Take on Psychedelics in 2022

“After the Ecstasy, the Laundry” – Shayla Love’s Take on Psychedelics in 2022

Post published:January 19, 2023
Post category:2022 Year in Review

Read more about the article Psychedelics 2022: A Year in Review

Psychedelics 2022: A Year in Review

Post published:January 19, 2023
Post category:2022 Year in Review

Read more about the article PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

Post published:January 18, 2023
Post category:Press Release

Read more about the article Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements

Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements

Post published:January 18, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Post published:January 17, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

Post published:January 17, 2023
Post category:Press Release

Read more about the article First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026

First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026

Post published:January 15, 2023
Post category:Press Release

Read more about the article Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden Sitzung des Typs C vor, die von der FDA für die geänderte Prüfplanvereinbarung der klinischen Phase-III-Studie für Bucillamin zur Behandlung von COVID-19 genehmigt wurde

Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden Sitzung des Typs C vor, die von der FDA für die geänderte Prüfplanvereinbarung der klinischen Phase-III-Studie für Bucillamin zur Behandlung von COVID-19 genehmigt wurde

Post published:January 15, 2023
Post category:Press Release

Read more about the article Psychedelic Bulletin #129: New Year, New Psychedelic Bills; WHO Dubs 5-MeO-DMT ‘Mebufotenin’

Psychedelic Bulletin #129: New Year, New Psychedelic Bills; WHO Dubs 5-MeO-DMT ‘Mebufotenin’

Post published:January 15, 2023
Post category:Psychedelic Bulletin

Read more about the article Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Post published:January 15, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.